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PENJANAAN PERPUSTAKAAN FAJ PAPARAN DOMAIN ANTIBODI 
SINTETIK TUNGGAL UNTUK APLIKASI DIAGNOSTIK MOLEKUL 
 
ABSTRAK 
 
 
Antibodi domain telah dieksploitasi secara meluas sebagai perancah untuk 
penjanaan perpustakaan antibody sintetik kerana saiz tanpa bergantung dengan 
mekanisma lipatan mudah. Dalam kajian ini, penjanaan perpustakaan yang pelbagai 
menggunakan rangka manusia tunggal (VH3-23(DP47)) dan kepelbagaian sintetik 
diperkenalkan melalui kaedah mutasi rawak yang berlaku secara semula jadi dalam 
kawasan kaset saling melengkapi (CDR), CDR1,CDR2 dan CDR3 pada rantaian 
berat telah menghasilkan 10^9 saiz perpustakaan. Kepelbagaian sikuen bagi semua 
CDR dapat ditentukan hasil daripada 28 klon yang dipilih secara rawak. Daripada 28 
klon, 18 klon telah dipulihara dengan kepelbagaian panjang CDR3 yang berbeza dan 
juga kepelbagaian dalam sisa amino asid. Kualiti perpustakkan yang dihasilkan dapat 
dinilai melalui proses seleksi terhadap dua jenis antigen protein; penyakit dan protein 
pendarfluor. Pelbagai klon sasaran unik khusus telah diperolehi bagi kebanyakan 
antigen. Walau bagaimanapun, terdapat 2 antibodi monoclonal yang telah berjaya 
diraih hasil daripada seleksi dengan Mycobacterium tuberculosis 16 kDa Hsp antigen 
(Mtb 16 kDa Hsp) yang berpotensi untuk digunakan untuk tujuan teraputik. 
Kesimpulannya, himpunan kepelbagaian perpustakaan naïf boleh digunakan pada 
masa hadapan untuk menyaringi antibodi pengikat dengan antigen berpotensi yang 
lain. 
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CONSTRUCTION OF A SYNTHETIC SINGLE DOMAIN ANTIBODY 
PHAGE DISPLAY LIBRARY FOR MOLECULAR DIAGNOSTIC 
APPLICATIONS 
 
ABSTRACT 
 
Domain antibodies have been widely exploited as a scaffold for the 
generation of synthetic antibody libraries because of their relatively small size and 
simple folding mechanism. In this study, the generation of a highly diverse library  
using a single human framework (VH3-23(DP47)) and synthetic diversity introduced 
by randomly mutating naturally occurring within complementarity-determining 
regions (CDRs) CDR1,CDR2 and CDR3 of heavy chain yielded a library size of 
10^9. The sequence diversity of all CDRs was determined from 28 randomly 
selected clones. Out of the 28 clones, 18 clones were conserved with different length 
of CDR3 and highly diverse amino acids residues. The quality of the library was also 
validated by panning against two different types of protein antigens; diseases and 
fluorescent proteins. Multiple unique target specific clones were obtained for most 
antigens. However, two monoclonal antibodies were successfully raised against 
Mycobacterium tuberculosis 16 kDa Hsp (Mtb 16 kDa Hsp) antigens which could 
potentially be used for therapeutics. In conclusion, the diverse repertoire of the naïve 
library can be used in the future to screen for binders against other potential antigens. 
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CHAPTER 1 
 
1.0 Introduction 
The rise of recombinant antibody technology was made possible by a 
combination of innovations like polymerase chain reaction technology (Orlandi, 
Güssow et al. 1989; Hoogenboom 2005), phage display technology  (Siegel 2002) 
and evolution of online data collection of human immunoglobulin genomic 
sequences (Hust and Dübel 2004; Benhar 2007). For the past decade, the exploration 
of an array of recombinant antibody libraries for various applications was carried out. 
Improvements in molecular biology have paved the way towards improving 
parameters in order to produce libraries with higher diversity, larger sizes and better 
quality. Numerous studies have been done with the aspiration to mimic the uniquely 
human adaptive immune system that constantly generates diverse binding capacities 
of antibodies in a miniature sized test tube. 
In 1975, the very first monoclonal antibody was introduced via hybridoma 
technology that requires the immunization of animals (Muyldermans 2001). 
Generation of these monoclonal antibodies involved the incorporation of myeloma 
cells with antibody producing spleen cell (Kohler and Milstein 1975). Thus, the 
hybrid will feature traits from both cells by maintaining immortality and antibody 
production. Inevitably, the use of hybridoma technology to produce monoclonal 
antibodies suffered several setbacks (Hoogenboom 2005). Some of the main 
disadvantages of murine derived antibodies are the use of animal host, longer periods 
of time required for production, unable to generate functional human antibodies and  
incapable of generating antibodies against toxic antigens (Geyer, McCafferty et al. 
2012). It is these bottlenecks that have made hybridoma technology an unattractive 
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prospect for antibody production. The degree of freedom on offer for researchers by 
recombinant antibody technology has led to it gaining popularity in diagnostic 
applications (Marks, Hoogenboom et al. 1991; Holt, Enever et al. 2000; Siegel 2002; 
Ohara, Knappik et al. 2006). 
In vitro display methods such as phage display, yeast display, ribosome 
display technology were introduced as a major alternative for the generation of 
recombinant human monoclonal antibodies (Barbas, Kang et al. 1991; Silacci, Brack 
et al. 2005). It is an in vitro process that is independent of any regulation by the 
immune system. The most widely used method is the phage display technology. This 
method employs the use of filamentous bacteriophage M13 as the display machinery 
(Barbas and Barbas 1994). The ability of a bacteriophage to present a recombinant 
target on its surface was first evident with the pioneering work by George Smith with 
peptides. 
 
1.1 Phage Display Antibody Library 
Phage display has earned its spotlight as the gold standard in vitro display 
system that caters for the increasing demand for the generation of peptides and 
recombinant proteins especially antibodies. The underlying concept of this display 
technology is the physical linkage between genotype and phenotype. The robustness 
of this technology lies in its ability to control and manipulate selection conditions. It 
is therefore, independent of any regulation by the immune system. In addition, 
antibodies can be harvested without having to go through animal immunization. Over 
the last decade, in vitro display methods have been very successful in the generation 
of diagnostic and therapeutic antibodies.  
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In general, there is an array of bacteriophages that has been exploited for 
surface display such as T7, T4 and Lambda. However for phage display systems, the 
most commonly used bacteriophage is the Ff class of filamentous phage. The Ff 
phage comprises of M13, f1 and fd that belongs to the inoviridae family that infects 
gram negative bacteria bearing the F-episome. It is a long rod like shape particle that 
is made up of coat proteins encapsulating the single stranded genome. The viral coat 
is mainly made up of 5 types of coat protein (pIII, pVIII, pIX, pVII, pVI). The 
unique feature of the filamentous phage virus is the non-lytic lifecycle that has paved 
the way for an in vitro tool to study the protein-protein interaction as well as 
peptides. Phage propagation under the non –lytic cycle has allowed the phage display 
system to function as a tool for surface display. In the early 1980s, George P. Smith 
demonstrated the display of peptides via the fusion to the gIII gene of filamentous 
phage surface. From this discovery, we are able to obtain information on the phage 
physical linkage between genotype and its phenotype. The successful presentation of 
peptides was achieved, the first phage derived antibody library for monoclonal 
antibody production was reported (Winter, Griffiths et al. 1994)  
  Given the technological advancements over recent years, many researches 
have attempted to display numerous proteins through fusion with different coat 
proteins. However, with several limitations for display on each coat protein, only pIII 
is vastly used to display large proteins. The major advantage of gIII fusion is that it 
can tolerate relatively large insert without compromising the integrity of the F-pilus 
infection. It’s worth mentioning that pVIII coat protein has also been used for display 
of proteins and peptides. On the contrary, this fusion suffers from few drawbacks. 
Because of the phage particles are vastly made up of pVIII coat protein, fusion of 
large proteins or peptide for display may compromise the stability and structure of 
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the phage particles (Iannolo, Minenkova et al. 1995). Moreover, the fusion to gVIII 
will correspond to avidity effects due to high copies of the protein being presented on 
the surface, hence hindering affinity binding. In addition, the favored detection 
system for M13 phage is based on antibodies to pVIII coat protein, therefore any 
alteration to the gene VIII may interfere with the phage detection. 
There are two ways for foreign proteins or peptides to be inserted as a fusion 
to the phage coat proteins. It can be carried out using the phage vector or phagemid 
vector system. In this study, the phagemid system with gene III fusion is employed 
for the synthetic antibody library construction. Phagemids in general, are plasmids 
with an existing E.coli plasmid origin of replication, multiple cloning sites and an 
antibiotic-resistance gene inclusive of an additional Ff phage-derived origin of 
replication and gene III or gene VIII. This addition allows for the phagemid to be 
packaged as single stranded DNA (ssDNA) in viral particles. Phagemids can 
function as normal plasmids or packaged as recombinant single stranded DNA in the 
M13 capsid with the aid of a helper phage (Azzazy and Highsmith 2002). The added 
advantage of using this phagemid system over phage vector is that soluble proteins 
can be readily expressed in E.coli host without having to undergo any form of 
alteration. 
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Figure 1.1 : Illustration of filamentous phage particle adapted from Eubanks 2007 
(Eubanks, Dickerson et al. 2007). The phage particles are in linear rod like shape in 
which consisting of single stranded DNA and five coat proteins. pVIII coat protein 
also known as major coat protein makes up the vast structure of the phage protein 
capsid. Fusion of foreign proteins and peptides are usually to the gene VIII and gene 
III thus will be displayed fusion to pVIII and pIII coat protein. 
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1.2 Antibody Format 
The classical format of antibodies are represented graphically as a Y-shape 
structure (Figure 1.2) with two identical ends (Wood 2006). At N-terminus, a heavy 
chain is linked via interchain disulphide bonds to a light chain to generate the 
Fragment Antigen Binding (Fab) (Rader and Barbas 1997).  The binding pockets of 
the antibody is derived from the variable light and variable heavy domains within the 
Fab structure (Huston, Margolies et al. 1996). The advancement of recombinant 
antibodies through phage display has led to a wide array of different forms of 
antibody formats to be introduced (Hudson 1998).  
To date, formats such as the human domain antibodies, camelid domain 
antibodies (Harmsen and De Haard 2007), single domain shark antibodies (Dooley, 
Flajnik et al. 2003), single chain fragment variable (scFv), tandem scFv, diabody, 
tetrabody, minibody and single chain fragment antigen binding have been 
extensively employed as formats for monoclonal antibody generation  (Andris-
Widhopf, Rader et al. 2000; Little, Kipriyanov et al. 2000; Holt, Herring et al. 2003; 
Hussack, Keklikian et al. 2012). Moreover, the limitation introduced by the folding 
machinery of Escherichia coli (Holliger and Hudson 2005) has  resulted in the 
preferred use of smaller fragments such as domain antibodies to be heavily utilized 
for phage display  (Holt, Herring et al. 2003; Dudgeon, Famm et al. 2009). Thus, the 
introduction of the current formats is essential for researchers to curb such 
limitations. 
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Figure 1.2 : Illustrations depicting the basic Y shape of an immunoglobulin and 
smaller antibody derivatives commonly used for phage display, Fab (Fragment 
antigen binding) and scFv (single chain fragment variable) adapted from Kierny 
2012 (Kierny, Cunningham et al. 2012). 
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1.3 Domain Antibody: Unique Biophysical Properties 
The first smallest known antigen-binding fragment coined as “nanobodies”, 
‘‘domain antibody’’, or ‘‘dAb’’ was identified when a murine VH repertoire was 
selected against the model antigen hen-egg lysozyme with high affinity and 
specificity (Andris-Widhopf, Rader et al. 2000). Unlike scFv which is twice the size 
and Fab, four times the size of dAbs (Holt, Herring et al. 2003), their relatively 
smaller size is well suited for phage display (Chen, Zhu et al. 2009). Basically, dAb 
is the variable regions of either the heavy (VH) or light chains (VL) of 
immunoglobulins (Holt, Herring et al. 2003). 
Recent commercial interest revolves around manufacturing humanized 
antibody with high specificity and affinity for potential diagnostic and therapeutic 
applications (Brekke and Sandlie 2003). The production of domain antibodies brings 
about the advantages over the use of conventional antibodies. To add to its 
commercial value, the antibody produced must meet the requirement of biophysical 
properties (Harmsen and De Haard 2007) such as high yield and soluble expression  
(Muyldermans 2001), heat stability (Goldman, Anderson et al. 2006) such as 
resistance to proteolysis, resistance to harsh condition (Dona, Urrutia et al. 2009) 
such as chemical degradation (Wang, Singh et al. 2007), aggregation and 
denaturation. 
Initial studies of domain antibody showed that the expression and solubility 
of the first murine VH domain antibodies were low. The selection of the VH domain 
was done in mouse with the presence of a cognate VL, therefore, it was thought that 
the absence of the VH-VL hydrophobic interface contributed to the instability of the 
structure. After the setbacks, a modification was introduced in cloning of camelid 
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VHH domains. It was found that the solubility improved due to a hydrophilic 
mutation of a tetrad at the VL interface. Soon after, similar modifications of residues 
at positions 44, 45 and 47 was done in human VH domains with those frequently 
found in camel VHH domains. This approach is best known as ‘camelisation” 
(Davies and Riechmann 1994; Conrath, Vincke et al. 2005). However, despite having 
to overcome aggregation, the modified VH domains remained expressed at low 
yields and relatively unstable due to the deformation of the ß-sheet.  
 In resolving this issue, many researchers studied the effect of the VHH tetrad 
on solubility (Barthelemy, Raab et al. 2008) which resulted in a VH dAb library 
produced based on a murine germline gene with a substitution at the VL interface. 
Phage display panning was done with monomeric IgG-specific dAb and found to be 
soluble at a concentration of 2 mM (Holt, Herring et al. 2003). On the same note, 
good expression of fragments selected from the llama dAb library was attributed to 
the framework substitutions that differs from the VHH tetrad. Mutation and 
manipulation of the CDRH3 loop length also plays an important role to achieve good 
expression and solubility of the VH antibody (Riechmann and Muyldermans 1999). 
Besides having good expression yield and solubility, another attractive 
property of several camelid VHH domains and llama VH domains is the heat 
stability (Dudgeon, Famm et al. 2009). In general, antibodies and their fragments 
derived from human VH dAbs tend to aggregate irreversibly upon heat denaturation. 
However, it was reported that when camel and llama VHH domains (Dolk, van Vliet 
et al. 2005) were subjected to heat ranging between 80–90⁰C, they were able to 
maintain its antigen binding specificity despite prolonged incubation at high 
temperatures. Advancements made to cater for the thermo stability includes site-
directed mutagenesis based approaches for directed evolution of antibodies. 
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Undoubtedly, successful isolation of recombinant antibodies from libraries 
depend heavily in the quality of the libraries produced. Factors such as the number of 
correctly folded functional antibodies have brought a paradigm shift towards 
developing human domain antibody. An example of recent studies showed functional 
antibody of HEL4 domain antibody library mimicking the natural human immune 
response designed with only CDR3 diversity (Mandrup, Friis et al. 2013).  This 
library also includes mutations of the amino acid composition with regards to the 
positions critical for the folding and aggregation of domain antibodies.  
With regards to dAbs high affinity and specificity, their small size and short 
half-life are best suited for targeting antigens in tissue and blood vessel where 
penetration is often obstructed and for clearance purpose. For example in tumour 
cells, dAb can be used to assist delivery of specific toxins to the tumour cells in a 
short time without damaging healthy cells. However, in some applications, such as in 
cancer treatment (Revets, De Baetselier et al. 2005) in which the target antigen 
resides in the blood stream, prolonged serum half-life is crucial to maximize time for 
antibody antigen reaction to minimizes the dosage amount. 
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Figure 1.3 : Schematic representation of antibody formats ranging from conventional 
whole antibody to variable heavy and variable light chain domain antibody as the 
smallest unit (Chakravarty, Goel et al. 2014). 
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1.4 Synthetic Antibody Technology 
The rise of synthetic antibody stems from the limitation of natural repertoire 
diversity. For the past twenty years, studies have shown a particular interest in 
producing antibody with high affinity antigen-binding sites by introducing diversity 
mutation in CDR loops. The construction of semi- or fully synthetic antibody library 
genes were assembled using chemically synthesized DNA. One of the classical 
methods of in-vitro antibody production derived from the natural antibody genes is 
via PCR.  Naïve antibody repertoires via synthetic platforms are not biased for 
binders of any particular antigen and bypass the redundancies of naturally occurring 
antibody. Hence, the advantage of synthetic antibody over the natural repertoire is 
that it provides a wider diversity for any type of target.  
Notably, technical advances have allowed the development of highly 
functional synthetic antibody libraries that rival or even exceed the recognition 
potential of natural immune systems. The first semi-synthetic library was reported in 
1992 by Nissim and colleague with a human VH genes repertoire from 49 human 
germline VH gene segments with combinatorial synthetic CDR3 of five or eight 
residues (Hoogenboom and Winter 1992; Griffiths, Williams et al. 1994). Later on, it 
was again followed up with a ‘single pot’ human scFv library built from a diverse 
repertoire of in vitro human VH gene segments assembly with random nucleotide 
sequence for CDR3 lengths between 4 – 12 residues (Benhar 2007). 
The second generation of synthetic platform is based on a more limited 
collection of variable domain genes however, emphasizing more on robustness. The 
overall design took into consideration the yields of functional antibody fragments 
based on cellular folding in the E. coli expression machinery (Welch, Govindarajan 
et al. 2009). Since then, Pini’s group explored a semi synthetic antibody library that 
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was prepared using a single VH (DP47) and Vκ (DPK22)(Pini and Bracci 2000). The 
VH component of the library was created using partially degenerate primers in a 
PCR-based method to introduce random mutations at positions 95 – 98 in CDR3. It 
was found that creating antibody libraries starting from well-expressed frameworks 
was able to retain the diversity and stability (Hoogenboom, de  ru  ne et al. 1998). 
The ‘HuCal’ libraries were constructed with a more diverse sequence space 
although it is confined by the limited set of variable domain scaffolds (Benhar 2007). 
All the genes assembled were synthetically synthesized with a total of seven VH and 
VL (four Vκ and three Vλ) germline families that accounts for more than 95% of the 
human antibody diversity (Knappik, Ge et al. 2000). In addition, the genes were also 
optimized for expression in E. coli. The design of the library was based on cloning 
the V genes of scFv in all 49 combinations into a phagemid vector. Diversity was 
introduced in the CDR3 cassettes via generation of mixed trinucleotides sequences 
by substitution CDR3 regions of the master genes. Interestingly, the outcome of the 
library selection has resulted in obtaining high affinity binders with Kd between 10^9 
M and 10^10 M. The variation of the CDR3 cassettes resulted in a highly diverse 
library producing antibodies against a vast number of antigens with high affinity. 
 
1.5 Synthetic Domain Antibody Generation 
Interestingly, the unique nature of generating highly diverse antibodies 
against a plethora of antigens by the immune system has intrigued researchers to 
mimic such processes in vitro with synthetic gene platforms. The genetic sequence of 
the variable domain is chemically synthesized with the introduction of randomization 
at fixed positions corresponding to the CDR of the variable domain with a fixed 
framework  (Rothe, Urlinger et al. 2008; Yang, Kang et al. 2009; Prassler, Thiel et al. 
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2011). These degenerate oligonucleotides function as substitutes for the naturally 
occurring in vivo diversity. Synthetic platforms also take into account the variation in 
length of the CDR regions to fully maximize the diversity.  
These oligonucleotides are designed using highly randomized codons which 
are used to code for unspecified amino acids. The generation of amino acids 
sequence depends on the codon usage. There are two commonly used codon scheme 
of encoding unspecified amino acids sequences; 1) NNK ( A/T/C/G  as an equimolar 
representation of N and K codes for G/T ) 2) NNS ( N represents four bases and S 
codes for G/C) (Barbas, Burton et al. 2001). These schemes produce 32 codons with 
one stop codon. N in general, produces 64 possible codons, hence coding for 20 
amino acids. The most commonly used is NNK as it is able to produce high 
frequency of stop codon when used to encode for very large peptide consisting of 
more than 50.  
Construction of recombinant domain antibody requires the chemically 
synthesized genes to be assembled in a manner that resembles the complete gene 
sequence. The first method of assembly was introduced by Stemmer and colleagues 
where full-length genes were generated  (Stemmer, Crameri et al. 1995). This 
approach is known as the conventional one-pot gene assembly (Prodromou and Pearl 
1992; Stemmer, Crameri et al. 1995; Wu, Wolf et al. 2006). It is an annealing and 
assembling process by incorporating the mixture of all synthetic oligonucleotide in a 
single step PCR.  However, due to the variation in the length of degeneracy, it is 
rather difficult for gene assembly via the conventional method of polymerase chain 
reaction. One-pot gene assembly is likely less efficient for degenerate 
oligonucleotide with higher complexity as PCR is known to work well with a fixed 
sequence and not randomized sequences (Young and Dong 2004). Confined by the 
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limitation, two-step approaches have been proposed to assist in the assembly of 
genes with higher complexity for example by two-step PCR (Cherry, 
Nieuwenhuijsen et al. 2008), ligation chain reaction of fragmented segments (Au, 
Yang et al. 1998), gap filling and ligation (Ostermeier 2003).  
Two-step PCR methods involve the assembly of multiple overlapping 
oligonucleotides by PCR to generate the template DNA followed by the 
amplification of the DNA template with two outermost oligonucleotides as primers. 
The ligation chain reaction confers ligation of smaller fragments to form a unit and 
subsequently amplified by PCR.  The ligation chain reaction method however is 
slightly similarl of the ligation chain reaction wherein, the genes are assembled by 
polymerase gap filling in by ligating the ends together. Despite numerous proposed 
approach proposed, it is worth noting however that these method are not routinely 
used. 
 
1.6 Antibody Selection by In Vitro Panning  
Generation of antibodies by the immune system is involves the B cell 
repertoire where the V genes segments have undergone rearrangement.  As a result, a 
single antibody is displayed on the surface of the each cell. The selection process 
occurs by the interaction between antibodies with the antigen. Selected antibodies 
will either segregate to short-lived plasma cells or to long-lived memory cells in 
lymph nodes, spleen, and bone marrow (Winter, Griffiths et al. 1994). For memory 
cells, the V genes of the selected antibodies will undergo hyper mutation. At this 
point, binding affinity may be improved with successive selection with antigen. With 
regards to mimicking the whole process of B cell antibody generation process, 
“panning” or “biopanning” is used.  iopanning refers to the iterative in vitro process 
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of antibody selection from antibody libraries  based on target affinity (Kretzschmar 
and von Rüden 2002).  
There are several conditions that need to be taken into consideration during 
the selection process. The first factor is the imperative proficiency of isolating the 
gene pool to construct an antibody library with high diversity, capability of 
expressing functional antibody fragment in soluble form and lastly, the efficiency of 
simultaneous expression and display of genetic information being packaged. The 
population of target specific antibodies are enriched relative to the number of 
panning rounds (Mullen, Nair et al. 2006).  
Target antigens are commonly coated on various solid phase. The most 
common solid phase used are nitrocellulose, magnetic beads, agarose columns, 
monolithic columns, polystyrene tubes and 96 well microtitre plates (Kontermann 
and Dübel 2010). The solid phase bound phages are subjected to stringent washing to 
eliminate nonspecific binders. The subsequent step is then followed by recovery of 
the bound phages by elution.  This process can either be by competitive elution 
(Krishnaswamy, Kabir et al. 2009) or harsh acidic (Barbas, Kang et al. 1991) or 
alkaline condition (Marks, Hoogenboom et al. 1991). Phage recovery or rescue plays 
a pivotal role in the whole panning process as this will ensure retrieval of high 
affinity binders. The phages are normally grown in bacterial culture for amplification 
thus the recovered phages can be subjected to further rounds of selection.  Moreover, 
for each round of panning, phages can be enriched 20-1000 fold (McCafferty, 
Griffiths et al. 1990). 
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1.6.1 Panning Via Conventional Method (Immunotubes and Microtitre Plate) 
Prior to selection, the target antigens are coated on the surface of the solid 
phase for presentation. Figure 4 shows the overall illustration of the conventional 
panning process. This will be followed by an incubation step with the antibody 
bearing phage particles to allow binding of antibodies to the antigen. Parameters such 
as physical, chemical or biological are essentially introduced  (Lee, Iorno et al. 
2007). Stringent washing steps are necessary to ensure the removal of unbound 
phage particles from bound phage particles. Discrepancy in the washing approach 
will result in the variation of enriched clones. Lastly, an elution step can be 
conducted in many ways either by enzymatic digestion, pH shift or competitive 
antigen elution. The eluted phage particles are then enriched by infection of E. coli. 
At this time, the phage particles can either be repackaged to be used in the 
subsequent panning round or for final analysis.  
After 4 to 6 rounds of panning, identification of bound phage can be 
evaluated by antibody presenting phage or in the soluble form of antibodies on an 
immunoassay format  (Walter, Konthur et al. 2001). The positive clones will then be 
sequenced to obtain the genotypic information pertaining to the positive clone. As 
the genetic information of the clone is now available, modifications to the antibody 
can be done and produced in different host depending on the platform the antibodies 
will be used in. The availability of the genetic information of the antibodies would 
also facilitate additional modifications in terms of stability and affinity maturation 
(Pini and Bracci 2000).  
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Figure 1. 4 : Biopanning protocol adapted from Kügler 2013 (Kügler, Zantow et al. 
2013). (a) Pooled phage library will be subjected to panning (b) Antigens are 
immobilized onto solid surfaces and blocked to ensure nonspecific binding of phages 
onto the plastic surface. (c) The pooled phages will then be incubated with the 
immobilized antigen. (d) Unbound phages were then washed off by stringent 
washing subsequently followed by elution. (e) Antigen bound phage will be rescue 
by E.coli infection and followed by phage enrichment. (f) After every round of 
enrichment, the phage can either be subjected to phage ELISA or carried forward 
until the successive rounds completed.  
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1.6.2 Semi-Automated Panning 
Screening large sample sizes is tedious with conventional panning procedures 
that require repetitive rounds of panning, phage infection and propagation. However 
in semi-automated systems to streamline the laborious process of phage display, such 
as semi-automated magnetic bead-based antibody selection (Konthur, Wilde et al. 
2010), allows high-throughput screening of antibodies to be carried out with 
maximum convenience and minimal handling.  
Conventional method of antigen immobilization using 96 well microtiter 
plates involve two methods, either by adsorption of antigens to the plate surface 
(Bora, Chugh et al. 2002) or coating the plates with streptavidin to capture the 
antigen s(Välimaa, Pettersson et al. 2003). In contrast to using the microtiter plate, 
another alternative is by allowing biotinylated antigens to be coated onto the 
streptavidin magnetic beads (Cox and Ellington 2001). These magnetic beads have 
larger surface area which contributes to the efficiency in the panning process as 
compared to using microtiter plates.   
In practice, the panning method utilizes a pin-based magnetic particle 
processor (Kingﬁsher, Thermo) as shown in Figure 5(a). This machine enables the 
handling of 96 magnetic pins in which it is positioned similar to the common 96 well 
plate (Walter, Konthur et al. 2001; Rhyner, Konthur et al. 2003). The basic concept 
of using the processor is to streamline processes such as washing step, incubation 
times, and to conduct selections on same targets under different buffer conditions 
simultaneously. The software-driven procedure dictates the transferring process of 
magnetic particles between wells by capture and release motions shown in Figure 
5(a). The rod-shaped magnets are covered with plastic caps during the transferring 
process to prevent contamination.  However, the automation process only involves 
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the panning procedure wherein the subsequent step of phage rescue and enrichment 
is done manually. The advantage of semi-automated panning allows standardization 
of panning parameters and reduces background of non-specific binder when 
transferring from one well to another (Konthur and Walter 2002). The application of 
this method allows better reproducibility and a faster turnover rate in comparison to 
conventional plate based protocols. Therefore, the implementation of this method 
allows for high-throughput antibody discovery.  
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Figure 1.5 : Semi-automated panning. (a) Diagram of King Fisher Flex machine 
used to control automated beads panning. (b) Overall panning process from 
incubation to washing and plate switching is done automatically. Figure adapted 
from (Konthur, Wilde et al. 2010) 
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1.7 Statement of Problem  
A vast number of commercially therapeutic antibodies approved by the U.S. 
Food and Drug Administration are full-size antibodies of IgG1 format at about 150 
kDa size (Holt, Herring et al. 2003). Due to their relatively large-size, these 
molecules have limitations in terms of poor penetration into tissues (e.g., solid 
tumors) and eventually results in weak binding to functionally important regions 
(Dimitrov and Marks 2009). The use of using smaller formats can bring about 
therapeutic relevance. As an example, the human immunodeficiency virus envelope 
glycoprotein that can only be access by smaller molecules (Labrijn, Poignard et al. 
2003). Therefore, by decreasing the size of the molecule it can aid tissue penetration 
(Yokota, Milenic et al. 1993). 
  Over the last decade, a large amount of work has been focused on the 
development of alternatives for smaller novel scaffolds. (Holt, Herring et al. 2003; 
Holliger and Hudson 2005; Dimitrov and Marks 2009). Amongst the most explored 
scaffold includes the relatively small domain antibody, which comprises of only the 
domain antibodies and synthetic domain antibodies for various fields of research.  
Most domain antibodies are derived from camelids, sharks and murine. This is 
because fully human domain scaffolds of the variable gene repertoire are more likely 
to aggregate.  Since then, human heavy chain variable fragments (VH) have been 
compared with those found naturally in camelids.  
The determining factor for successful isolation of these antibodies relies 
heavily on the quality of the library generated. Among the critical factors are based 
on the diversity of the libraries as well as the functionality (Prassler, Thiel et al. 
2011). While most of the studies conducted on the synthetic human domain antibody 
tackles the issue of library construction (Silacci, Brack et al. 2005), biophysical 
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properties such as proper protein folding (Forrer, Jung et al. 1999) and  aggregation 
(Dudgeon, Famm et al. 2009) or diversity (Mondon, Dubreuil et al. 2008; Yang, 
Kang et al. 2009).  To circumvent this problem, mutational studies have been 
conducted to understand the factors attributed to these problems.  
The main focus for the antigen binding specificity lies within the CDR region 
of the variable domain. In the early stages, in depth studies of domain antibody 
sequence analysis have found that aggregation is likely to occur at the regions in or 
adjacent to the CDR regions. Thus, the generation of synthetic domain antibodies 
will allow for design of highly stable frameworks. Introducing diversity artificially 
will eliminate any bias introduced by the host immune system. A full control of the 
amino acid composition in the CDRs is possible by using the trinucleotide synthetic 
design. Knappik et al pioneered a rather complex library by introducing diversity in 
the CDR3 cassette in both variable heavy and light chain thus incorporating it in all 
49 combination into phagemid vector (Knappik, Ge et al. 2000). 
As more antibody sequence information was generated, several different 
approaches have been proposed to improve diversity. Christ and his group developed 
a synthetic human domain antibody library where the diversity was introduced in all 
three of the CDR region (Lee, Iorno et al. 2007) in the heavy variable region to be 
used in screening a wide array of antigen. In this study, the human domain antibody 
constructed will be based on a known antibody framework that is reported to have 
good solubility and stability (Lee, Liang et al. 2004; Mandrup, Friis et al. 2013). 
Similarly, the method introduced in this study is aimed to focus on the assembly of 
highly diverse genes of all three CDR regions with a defined single framework using 
single-pot synthesis. The CDR lengths were determined via analysis of the average 
length of CDRs naturally available. 
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  The introduced method would help to establish a synthetic human domain 
antibody library with unique and diverse CDR regions for functional antigen binding 
by the extension of CDR-H2 and CDR-H3 distribution length. As more disease 
specific biomarkers are being discovered, one of the major bottlenecks for the 
development of diagnostic tests or even for basic research is the availability of 
specific antibodies against these targets. 
  Therefore, this study has been conducted specifically for the production of 
monoclonal antibodies against biomarkers with the use of a synthetic human domain 
library. The naïve synthetic library will be used for selection of binders against a 
wide range of disease specific recombinant antigen that can potentially be used in 
diagnostic or even therapeutics platform. 
 
1.8 Research Objectives 
1. To design, assemble and clone a collection of synthetic human antibody variable 
heavy genes 
2. To generate a highly diverse in-house synthetic domain antibody phage display 
library. 
3. To identify monoclonal domain antibodies for potential binders against disease 
specific recombinant antigen. 
